Literature DB >> 9839621

Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner.

C Brekken1, C de Lange Davies.   

Abstract

Hyaluronidase has gained increasing interest as an adjuvant in local and systemic cancer therapy, despite the incomplete knowledge of its physiological function. To this end, direct intratumoral injection of bovine testicular hyaluronidase (500, 1600 or 7500 U in 50 microl phosphate-buffered saline (PBS)) was performed in orthotopic (o.t.) osteosarcoma xenografts grown in the hind leg of nude mice. Control tumours received 50 microl PBS alone or supplemented with 10% bovine serum albumin (BSA). Central tumour interstitial fluid pressure (IFP) and mean arterial blood pressure (MABP) were measured using the wick-in-needle technique and after cannulation of the carotid artery, respectively. IFP was 32 +/- 8 mmHg (n = 44, mean +/- SD) in untreated tumours and there was a significant correlation between tumour IFP and volume (P < 0.01). The hyaluronidase injection reduced IFP to 63-84% after 1 h compared with controls (P < 0.05) and in a non-linear concentration-dependent manner. MABP was not affected significantly. In conclusion, an intratumoral hyaluronidase injection might reduce IFP temporally in solid osteosarcoma xenografts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839621     DOI: 10.1016/s0304-3835(98)00202-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

Review 1.  Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.

Authors:  Lei Miao; C Michael Lin; Leaf Huang
Journal:  J Control Release       Date:  2015-08-12       Impact factor: 9.776

2.  Kinetic analysis of hyaluronidase activity using a bioactive MRI contrast agent.

Authors:  Liora Shiftan; Michal Neeman
Journal:  Contrast Media Mol Imaging       Date:  2006 May-Jun       Impact factor: 3.161

3.  YOYO as a dye to track penetration of LK15 DNA complexes in spheroids: use and limits.

Authors:  Heather A D Perry; Amer F Alhaj Saleh; Harmesh Aojula; Alain Pluen
Journal:  J Fluoresc       Date:  2007-10-24       Impact factor: 2.217

4.  Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

Authors:  Marc-André Fortin; Alexei V Salnikov; Marika Nestor; Nils-Erik Heldin; Kristofer Rubin; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-03       Impact factor: 9.236

5.  Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Authors:  Alex B Blair; Victoria M Kim; Stephen T Muth; May Tun Saung; Nathalie Lokker; Barbara Blouw; Todd D Armstrong; Elizabeth M Jaffee; Takahiro Tsujikawa; Lisa M Coussens; Jin He; Richard A Burkhart; Christopher L Wolfgang; Lei Zheng
Journal:  Clin Cancer Res       Date:  2019-06-11       Impact factor: 12.531

Review 6.  Exploring the tumor microenvironment with nanoparticles.

Authors:  Lei Miao; Leaf Huang
Journal:  Cancer Treat Res       Date:  2015

7.  Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.

Authors:  Mariana Malvicini; Esteban Fiore; Valentina Ghiaccio; Flavia Piccioni; Miguel Rizzo; Lucila Olmedo Bonadeo; Mariana García; Marcelo Rodríguez; Juan Bayo; Estanislao Peixoto; Catalina Atorrasagasti; Laura Alaniz; Jorge Aquino; Pablo Matar; Guillermo Mazzolini
Journal:  Mol Ther       Date:  2015-06-24       Impact factor: 11.454

Review 8.  Intratumoral drug delivery with nanoparticulate carriers.

Authors:  Hillary Holback; Yoon Yeo
Journal:  Pharm Res       Date:  2011-01-07       Impact factor: 4.200

9.  Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model.

Authors:  Matthias Hofmann; Emmet McCormack; Maja Mujić; Maila Rossberg; August Bernd; Jürgen Bereiter-Hahn; Bjørn Tore Gjertsen; Helge Wiig; Stefan Kippenberger
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

Review 10.  Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Authors:  Ameya R Kirtane; Stephen M Kalscheuer; Jayanth Panyam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.